Clinical research related to the use of PI3Kβ inhibitors is more advanced in prostate or breast cancers; nonetheless, PI3Kβ-specific inhibitors are promising therapies for other PTEN-deficient cancers such as melanoma, glioblastoma and bladder. This evidence concerns the gene PTEN and breast carcinoma.